---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-266959"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:10:03.911301+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Acadia Q3 revenue $278.6M (+11% YoY); net income $71.8M; raises FY 2025 guidance

## Summary
- Q3 net product sales: NUPLAZID $177.5M (+12% YoY), DAYBUE $101.1M (+11% YoY).
- Q3 net income $71.8M ($0.42 diluted EPS) vs. $32.8M ($0.20) in Q3 2024.
- Full-year 2025 total revenue guidance raised to $1.07-1.095B from $1.045-1.095B.
- NUPLAZID guidance raised to $685-695M; DAYBUE guidance tightened to $385-400M.
- Cash & investments $847M at Sept 30, 2025 vs. $756M at Dec 31, 2024.

## SEC filing metadata
- accession: 0001193125-25-266959
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000119312525266959/0001193125-25-266959-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000119312525266959/acad-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-266959
- JSON: https://secwatch.observer/filing/0001193125-25-266959.json
- Plain text: https://secwatch.observer/filing/0001193125-25-266959.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.